Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

[1]  B. Landi,et al.  Traitement des tumeurs stromales digestives , 2004 .

[2]  P. Angeli,et al.  A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. , 2004, Gastroenterology.

[3]  J. Blay,et al.  Doppler-Ultrasonography with perfusion software and contrast medium injection as an early evaluation tool of gastro intestinal stromal tumor (GIST) treated by imatinib: Results of a prospective study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Blay,et al.  Continuous vs intermittent imatinib treatment in advanced GIST after one year: A prospective randomized phase III trial of the French Sarcoma Group , 2004 .

[5]  J. Blay,et al.  Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD) - an international, intergroup study of the EORTC, ISG and AGITG. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Crowley,et al.  Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Joensuu,et al.  Gastrointestinal stromal tumors–a review , 2004, Acta orthopaedica Scandinavica. Supplementum.

[8]  J Nuyts,et al.  18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). , 2003, European journal of cancer.

[9]  M. Merli,et al.  Incidence and natural history of small esophageal varices in cirrhotic patients. , 2003, Journal of hepatology.

[10]  G. Demetri,et al.  Management of malignant gastrointestinal stromal tumours. , 2002, The Lancet. Oncology.

[11]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[12]  L. Sobin,et al.  Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.

[13]  W. El-Rifai,et al.  Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. , 2002, Human pathology.

[14]  K. Antman,et al.  Imatinib mesylate--a new oral targeted therapy. , 2002, The New England journal of medicine.

[15]  Sigrid Stroobants,et al.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.

[16]  M. V. van Velthuysen,et al.  The histopathological differential diagnosis of gastrointestinal stromal tumours , 2001, Journal of clinical pathology.

[17]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[18]  M. Zoli,et al.  Natural history of cirrhotic patients with small esophageal varices: a prospective study , 2000, American Journal of Gastroenterology.

[19]  D. Valla,et al.  Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-Speaking Club for the Study of Portal Hypertension. , 1999, European journal of gastroenterology & hepatology.

[20]  R. Franchis,et al.  ‘De novo’ development of esophageal varices in patients with a recent histologic diagnosis of liver cirrhosis , 1998 .

[21]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[22]  G. D’Amico,et al.  Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. , 1997, Bailliere's clinical gastroenterology.

[23]  D. Lebrec,et al.  Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats. , 1991, Journal of hepatology.

[24]  R. Groszmann,et al.  Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension. , 1991, The Journal of clinical investigation.

[25]  A. Ravaud,et al.  Incidence of large oesophageal varices in patients with cirrhosis: application to prophylaxis of first bleeding. , 1990, Gut.

[26]  G. Hommel.  A stagewise rejective multiple test procedure based on a modified Bonferroni test , 1988 .

[27]  E. Glatstein,et al.  Progression-free Survival in Gastrointestinal Stromal Tumours With High-dose Imatinib: Randomised Trial , 2006 .

[28]  R. Makuch,et al.  103 Multicenter randomized placebo-controlled trial of non-selective beta-blockers in the prevention of the complications of portal hypertension: final results and identification of a predictive factor , 2003 .

[29]  J. Lasota,et al.  Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.

[30]  M. Pinzani,et al.  Long course and prognostic factors of virus-induced cirrhosis of the liver. , 1997, The American journal of gastroenterology.

[31]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .